Related Experiment Video
Updated: Jan 19, 2026
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors
Suliman Almahmoud1, Haizhen A Zhong2
1Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198-6125, USA. suliman.almahmoud@unmc.edu.
Abstract:
The programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) is an immune checkpoint (ICP) overexpressed in various types of tumors; thus, it has been considered as an important target for cancer therapy. To determine important residues for ligand binding, we applied molecular docking studies to PD-1/PD-L1 complex inhibitors against the PD-L1 protein. Our data revealed that the residues Tyr56, Asp122, and Lys124 play critical roles in ligand binding to the PD-L1 protein and they could be used to design ligands that are active against the PD-1/PD-L1 complex. The formation of H-bonds with Arg125 of the PD-L1 protein may enhance the potency of the PD-1/PD-L1 binding.
Insights
Identifying key residues in programmed cell death ligand 1 (PD-L1) binding is crucial for developing novel cancer immunotherapies targeting the PD-1/PD-L1 immune checkpoint. Molecular docking revealed Tyr56, Asp122, and Lys124 are critical for PD-L1 ligand interactions.
Area of Science:
- Immunology
- Molecular Biology
- Computational Chemistry
Background:
- Programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) is an immune checkpoint (ICP) frequently overexpressed in tumors.
- This overexpression makes the PD-1/PD-L1 pathway a significant target for cancer therapeutics.
Purpose of the Study:
- To identify critical amino acid residues involved in ligand binding to PD-L1.
- To provide insights for designing novel inhibitors targeting the PD-1/PD-L1 complex.
Main Methods:
- Molecular docking simulations were performed on PD-1/PD-L1 complex inhibitors.
- Inhibitors were docked against the PD-L1 protein to analyze binding interactions.
Main Results:
- Residues Tyr56, Asp122, and Lys124 were identified as playing critical roles in PD-L1 ligand binding.
- The formation of hydrogen bonds with Arg125 on PD-L1 may enhance binding potency.
Conclusions:
- The identified key residues (Tyr56, Asp122, Lys124) are essential for PD-L1 ligand interactions.
- These residues can serve as a basis for designing potent and specific inhibitors for the PD-1/PD-L1 pathway in cancer therapy.
More Related Videos
09:40Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
Published on: September 28, 2018
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
02:40Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
02:18The Equilibrium Binding Constant and Binding Strength
02:04Protein-protein Interfaces
01:16Protein-Drug Binding: Mechanism and Kinetics
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...